ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2012

Abstract Number: 2684

Cerebrospinal Fluid IL-6 and Anti-NMDA Receptor NR2 Antibodies As Surrogate Markers for CNS Disease Severity in SLE

Shunsei Hirohata, Yoshiyuki Arinuma and Eisuke Ogawa, Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: autoantibodies, central nervous system involvement, interleukins (IL), neuropsychiatric disorders and systemic lupus erythematosus (SLE)

Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment V: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Neuropsychiatric manifestations occur in approximately one-half of patients with SLE and may cause substantial impairment of quality of life as well as disability. Among a variety of neuropsychiatric manifestations in SLE, acute confusional state (ACS) in diffuse psychiatric/neuropsychological syndromes (diffuse NP-SLE) is the most serious one. Of note, cerebrospinal fluid (CSF) IL-6 was found to be elevated in patients with NP-SLE, including diffuse NP-SLE and focal NP-SLE. Moreover, recent studies have demonstrated that CSF anti-NMDA receptor NR2 antibodies (anti-NR2) are associated with diffuse NP-SLE. However, the relationship of CSF IL-6 and anti-NR2 with the severity of NP-SLE remains uncertain. The current studies examined whether CSF IL-6 and ant-NR2 might be surrogate markers for the severity of NP-SLE.

Methods: CSF samples were obtained from 62 SLE patients who satisfied the 1982 ACR revised criteria when they showed active neuropsychiatric manifestations (44 patients with diffuse NP-SLE and 18 patients with neurologic syndromes [focal NP-SLE]) as well as from 20 control patients with non-inflammatory neurological diseases. CSF IL-6 was quantitated by bioassay using IL-6 dependent cell line MH60.BSF2.CSF IgG anti-NR2 were measured by ELISA using synthetic peptide containing the extracellular ligand-binding domain of NR2.

Results: CSF IL-6 was significantly elevated in diffuse NP-SLE compared with that in focal NP-SLE or in control patients. CSF anti-NR2 were also significantly elevated in diffuse NP-SLE compared with those in focal NP-SLE or in control patients (figure). Moreover, CSF IL-6 levels as well as CSF anti-NR2 were also significantly higher in ACS than in diffuse NP-SLE other than ACS (cognitive disorder, mood disorder, anxiety disorder and psychosis). Finally, CSF IL-6 levels were significantly correlated with CSF anti-NR2 in patients with NP-SLE (r=0.3732, p=0.0054).

Conclusion: These results demonstrate that CSF IL-6 as well as CSF anti-NR2 were most markedly elevated in ACS. The data therefore indicate that CSF IL-6 and anti-NR2 might be surrogate markers for the disease severity of NP-SLE. Finally, the positive correlation between CSF IL-6 and anti-NR2 suggest that anti-NR2 might be involved in the production of IL-6 within the CNS in SLE.


Disclosure:

S. Hirohata,
None;

Y. Arinuma,
None;

E. Ogawa,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cerebrospinal-fluid-il-6-and-anti-nmda-receptor-nr2-antibodies-as-surrogate-markers-for-cns-disease-severity-in-sle/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology